一、2000公里新藏铁路、1000亿独库公路、8000亿煤化工年内齐发，新疆基建订单海啸倒计时已 至！这些工程龙头有望分享万亿级盛宴 ； 二、 2283万患者仅54%用药！白癜风创新药催生百亿级市场，龙头药企稀缺红利一触即发 。 点击付费阅读，解锁市场最强音，把握投资机会！ ...

Group 1 - The report highlights a significant potential market for vitiligo treatments in China, estimating the market could exceed 20 billion yuan, driven by over 22 million patients suffering from the condition [3][48][49] - The current treatment landscape for vitiligo is limited, with existing therapies having various shortcomings, and there is an urgent need for effective, targeted medications [20][15][14] - The report identifies two key companies, Kangzheng Pharmaceutical and Tianen Pharmaceutical, as leaders in the development of innovative treatments for vitiligo, with promising clinical data expected soon [3][28][44] Group 2 - Kangzheng Pharmaceutical's ruxolitinib cream has shown strong clinical efficacy, with a 24-week F-VASI75 response rate of 50% in real-world studies, indicating its potential for significant market impact [36][31][32] - Tianen Pharmaceutical's CKBA ointment is in phase II clinical trials, with data expected in Q3 2025, showcasing a novel mechanism that effectively inhibits immune responses associated with vitiligo [44][47] - The report emphasizes the low competition in the domestic vitiligo drug development space, suggesting a favorable environment for new entrants to capture market share [27][48]